Emily Clarke

Emily Clarke

Auto-generated profile, based on publicly available information

Emily Clarke

Consultant in genitourinary medicine and HIV, Liverpool University Hospitals NHS Foundation Trust, Mount Vernon St, Liverpool L7 8YE United Kingdom

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2017 in International Journal of STD & AIDS
Verified
Journal Article
Open access
RPRajul Patel
Rajul Patel
OKOliver J Kennedy
Oliver J Kennedy
ECEmily Clarke
Emily Clarke
AGAnna Geretti
Anna Geretti
ANArvid Nilsen
Arvid Nilsen
EFElizabeth Foley
Elizabeth Foley
Genital herpes is one of the commonest sexually transmitted infections worldwide. Using the best available evidence, this guideline recommends strategies for diagnosis, management, and follow-up of the condition as well as for minimising transmission. Early recognition and initiation of therapy is key and may reduce the duration of illness or avoid hospitalisation with complications, including urinary retention, meningism, or severe systemic illness. The guideline covers a range of common clinical scenarios, such as recurrent genital herpes, infection during pregnancy, and co-infection with human immunodeficiency virus.

9 April 2015 in International Journal of STD & AIDS
Verified
Journal Article
Closed access
RPRaj Patel
Raj Patel
JGJohn Green
John Green
ECEmily Clarke
Emily Clarke
KSKanchana Seneviratne
Kanchana Seneviratne
NANaomi Abbt
Naomi Abbt
EFElizabeth Foley
Elizabeth Foley
These guidelines concern the management of anogenital herpes simplex virus infections in adults and give advice on diagnosis, management, and counselling of patients. This guideline replaces the 2007 BASHH herpes guidelines and includes new sections on herpes proctitis, key points to cover with patients regarding transmission and removal of advice on the management of HSV in pregnancy which now has a separate joint BASHH/RCOG guideline.

28 August 2013 in International Journal of STD & AIDS
Verified
Journal Article
Closed access
RPRupali R Patel
Rupali R Patel
SPSonali Patel
Sonali Patel
ECEmily Clarke
Emily Clarke
AKAhmed W Khan
Ahmed W Khan
BDBhavin Doshi
Bhavin Doshi
T(the European Collaborative Clinical Group (ECCG)
the European Collaborative Clinical Group (ECCG)
Men who have sex with men (MSM) are at particular risk for HIV/sexually transmitted infections (STI). To investigate the European guidance used for MSM STI and HIV screening, risk level profiling and how this translated to practice, we conducted a questionnaire survey of leading physicians in the European branch of the International Union against Sexually Transmitted Infections (IUSTI). We identified that most European countries have limited guidance on screening intervals for MSM. Where risk profiling is advised, it is often left to clinicians to weight different behaviours and decide on screening frequency. Our results suggest that European MSM STI and HIV testing guidelines be developed with clear and specific recommendations around screening intervals and risk profiling. These guidelines will be particularly helpful due to rapidly evolving models of sexual healthcare, and the emergence of new providers who may benefit from guidelines that require less interpretation.

30 September 2024 in International Journal of STD & AIDS
Verified
Journal Article
Closed access
ECEmily Clarke
Emily Clarke
RPRaj Patel
Raj Patel
DDDyan Dickins
Dyan Dickins
KFKaty Fidler
Katy Fidler
AJAllan Jackson
Allan Jackson
EFElizabeth Foley
Elizabeth Foley
This updated national UK guideline offers recommendations on the management of genital herpes simplex virus (HSV) in mothers and pregnant people during pregnancy and within 4 weeks following birth. It includes recommendations for first episode and recurrent HSV, HSV in preterm pre-labour rupture of membranes and in co-infection with HSV and HIV. Recommendations around management of the neonate are made, on prevention of postnatal transmission, management of breastfeeding, and the management of clinically discordant couples. This guideline is aimed at healthcare professionals working in sexual health clinics, maternity units, and those working on postnatal wards and neonatal units in the UK. However, the principles of the recommendations should be adopted across all services, including community care.

28 October 2024 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
COChloe Orkin
Chloe Orkin
RHRosalie Hayes
Rosalie Hayes
JHJoanne Haviland
Joanne Haviland
YWYuk Lam Wong
Yuk Lam Wong
KRKyle Ring
Kyle Ring
SPSara Paparini
Sara Paparini
Introduction: The equity-focused Implementing Long-Acting Novel Antiretrovirals study evaluated feasibility, acceptability, appropriateness of delivering on-label 2-monthly cabotegravir and rilpivirine (CAB + RPV) injections for human immunodeficiency virus (HIV)-1 therapy in clinics and community settings. Methods: The study, which mandated inclusive recruitment, was conducted May–December 2022 at 6 UK sites. Injections were delivered in clinic (month [M] 1–6) and in clinic or community setting according to patient choice (M6–12). Surveys were completed at baseline, M4, and M12 using validated measures for feasibility (FIM), acceptability (AIM), and appropriateness (IAM). Primary endpoint: proportion of participants agreeing that the injection and community setting were feasible (FIM ≥4) at M12. Fourteen participants completed interviews at baseline and M12. Results: Community settings offered by sites included: home visits (n = 3), HIV support organizations (n = 2), and community clinic (n = 1). Of 114 participants, 54% were female, 70% racially minoritized, and 40% aged ≥50 years. A total of 27/114 chose to receive injections in community settings. FIM/AIM/IAM scores at M12 were high for the injection (79.0–87.4%) and lower for the community setting (44.2–47.4%) overall. Subgroup analyses indicated differences in scores by gender and ethnicity. Among those who attended the community, FIM/AIM/IAM scores for the community setting at M12 were high (73.1–80.8%). Concerns about stigma, inconvenience, and losing access to trusted clinicians negatively influenced perceptions of receiving injections at community settings, amongst other factors. Conclusions: CAB + RPV injections were considered highly feasible, acceptable, and appropriate; however, few chose community delivery. Those that chose community delivery found it highly acceptable and feasible. Further exploration of CAB + RPV delivery in alternative community sites not offered (eg, primary care, pharmacies) is warranted. ClinicalTrials.gov: NCT05294159

7 October 2024 in International Journal of STD & AIDS
Verified
Journal Article
Open access
RPRaj Patel
Raj Patel
JGJohn Green
John Green
BMBenjamin Moran
Benjamin Moran
ECEmily Clarke
Emily Clarke
KSKanchana Seneviratne
Kanchana Seneviratne
EFElizabeth Foley
Elizabeth Foley
The guideline provides recommendations on the management of adults with anogenital herpes in the UK. Recommendations include diagnostic tests, management of the primary or first episode of anogenital herpes and recurrences, effectiveness of therapy, prophylaxis, and prevention of transmission between partners, as well as patient centred counselling.